Intelligent Bio Solutions Partners with SMARTOX to Expand Globally

Intelligent Bio Solutions Partners with SMARTOX for Global Reach
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is making strides in the medical technology realm, particularly in non-invasive testing solutions. Recently, the company formed a strategic partnership with SMARTOX, a Texas-based authority in drug and alcohol screening services. Through this collaboration, INBS will be able to introduce its innovative SmarTest Patch to international markets beyond the United States and Canada.
This new distribution agreement resonates with the long-standing relationship INBS has had with SMARTOX, which has previously acted as the distributor for INBS’s Intelligent Fingerprinting Drug Testing Solution. The aim is not just to expand the reach of the SmarTest Patch, but to enhance the overall portfolio of non-invasive drug testing solutions.
Introducing a New Standard in Drug Testing
The SmarTest Patch is poised to transform how drug detection is performed. This product utilizes continuous sweat-based detection over extended periods, thus offering a more efficient and non-invasive method for drug screening. Such advancements arrive at an opportune time, with the global drug testing market anticipated to grow significantly in the coming years, with estimates suggesting it could reach upwards of $18.6 billion.
Harry Simeonidis, President and CEO of Intelligent Bio Solutions, stated, "This partnership with SMARTOX is a natural progression of our relationship and enables us to extend a highly complementary technology to our existing markets.” This reflects the company’s vision to meet the evolving demands of sectors such as justice, rehabilitation, and workplace environments.
Broader Applications and Solutions
With the SmarTest Patch now integrated into its offerings, INBS can cater to both short-term and continuous detection needs in drug screening. The ability to provide flexible, non-invasive solutions positions the Company favorably as it continues its global expansion. Currently, Intelligent Bio Solutions delivers non-invasive solutions to over 450 clients spread across 24 countries, supporting needs in health, justice, and workplace sectors alike.
Strategic Focus on U.S. Market and Regulatory Compliance
In addition to its international growth efforts, INBS is keenly focused on increasing its footprint in the United States. A crucial part of this strategy includes securing FDA clearance for its fingerprint sweat-based drug testing technology, moving beyond solely forensic applications. Through proactive engagement with regulatory experts, INBS aims to bring its innovative solutions to U.S. organizations, which seek dignified and effective alternatives for drug screening.
About SMARTOX and Its Role
Founded in 2012, SMARTOX has established itself as a leading provider of drug and alcohol testing products and services in various sectors including healthcare, corporate, and education. The commitment of SMARTOX to advanced technology ensures the success of their product lines while paving the way for further innovations in forensic testing markets. Their partnership with Intelligent Bio Solutions will certainly enhance their collective offering and streamline testing services.
Innovative Approach of Intelligent Bio Solutions
Intelligent Bio Solutions Inc. has a transformative vision for portable testing, with its Intelligent Fingerprinting Drug Screening System at the core. This pioneering system revolutionizes drug screening through the analysis of fingerprint sweat, making it hygienic and cost-effective. With rapid sampling and results in under ten minutes, it is a valuable asset for organizations in safety-critical industries.
The company caters to diverse customer segments including construction, manufacturing, logistics, and drug treatment services, ensuring comprehensive solutions are available worldwide.
Frequently Asked Questions
What is the SmarTest Patch?
The SmarTest Patch is a non-invasive drug detection product from Intelligent Bio Solutions that utilizes continuous sweat-based testing for drug screening.
How will the partnership with SMARTOX benefit INBS?
This partnership enables INBS to broaden its market reach and offer new non-invasive drug testing solutions in international markets.
What is the importance of FDA clearance for INBS?
Gaining FDA clearance will allow INBS to expand its fingerprint sweat-based drug testing technology for use beyond forensic applications in the U.S. market.
What types of sectors will benefit from the SmarTest Patch?
Sectors such as justice, rehabilitation, and workplace environments will greatly benefit from the introduction of the SmarTest Patch.
What distinguishes the testing solutions offered by INBS?
INBS’s solutions are rapid, non-invasive, and designed to be hygienic and user-friendly, setting them apart in the drug testing industry.
About The Author
Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.